19978-25-7

Basic information

• Product Name: 2,6-dimethoxy-4-nitrophenol
• Synonyms: 2,6-dimethoxy-4-nitrophenol
• CAS NO: 19978-25-7
• Molecular Weight: 199.163
• Mol File: 19978-25-7.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 2,6-dimethoxy-4-nitrophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dimethoxy-4-nitrophenol(19978-25-7)
• EPA Substance Registry System: 2,6-dimethoxy-4-nitrophenol(19978-25-7)

Safety Data

• Hazardous Substances Data: 19978-25-7(Hazardous Substances Data)

Usage

Physical properties

yellow crystalline solid

Uses

synthesis of pharmaceuticals and dyes, intermediate in organic synthesis, reagent in biochemical research

Studied properties

potential antimicrobial and antioxidant properties

Hazards

considered hazardous due to toxicity and potential environmental impact

Upstream product

• 118-41-2 Eudesmic acid 
• 91-10-1 1,3-dimethoxy-2-hydroxy-benzene 
• 634-36-6 1,2,3-trimethoxybenzene 
• 6307-90-0 3,4,5-trimethoxy-1-nitrobenzene 
• 530-57-4 3,5-dimethoxy-4-hydroxybenzoic acid 

Downstream Products

• 15834-60-3 4-hydroxy-3,5-dimethoxyaniline 
• 27065-70-9 2-benzyloxy-1,3-dimethoxy-5-nitrobenzene 
• 957420-33-6 cyclopentyl N-[(2,6-dimethoxy-4-nitrophenoxy)acetyl]-L-leucinate 
• 957420-41-6 cyclopentyl N-[2-(2,6-dimethoxy-4-nitrophenoxy)ethyl]-L-leucinate 
• 957420-28-9 (2,6-dimethoxy-4-nitrophenoxy)acetic acid 
• 957420-39-2 (2,6-dimethoxy-4-nitrophenoxy)acetaldehyde 

Relevant articles and documents

SUBSTITUTED TRIAZINE COMPOUNDS AND USES THEREOF

The present invention relates to compounds of formula (I) : including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, hypercholesterolemia.

Design, synthesis, and biological evaluation of F-18-labelled 2, 4-diaminopyrimidine-type FAK-targeted inhibitors as potential tumour imaging agents

As a type of intracellular nonreceptor tyrosine kinase, focal adhesion kinase (FAK) can be highly expressed in most types of tumours and is thus regarded as a promising antitumour target. In this study, a series of novel 2,4-diaminopyrimidine FAK-targeted

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.